AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17361245 — intervention group
Group type: COMPARATOR
Intervention: 0.5% timolol GFS after switching from latanoprost
Number of subjects: 75
Study 17361245 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment periods for latanoprost
Number of subjects: 75
Study 17361245 — intervention group
Group type: COMPARATOR
Intervention: Combined treatment periods for timolol GFS
Number of subjects: 75
Study 16379620 — intervention group
Group type: EXPERIMENTAL
Intervention: AIR pulmonary delivery system (5-mg placebo powder of engineered particles)
Number of subjects: 12
Study 11927174 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine 5.0 mg
Number of subjects: 0
Study 11927174 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam 1.0 mg
Number of subjects: 0
Study 11927174 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9860397 — intervention group
Group type: EXPERIMENTAL
Intervention: CCK-8 infused intravenously (i.v.) at physiological doses
Number of subjects: 16
Study 9860397 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraduodenal (i.d.) oleate
Number of subjects: 16
Study 9860397 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 9860397 — intervention group
Group type: EXPERIMENTAL
Intervention: Loxiglumide (CCK-A receptor antagonist) pretreatment
Number of subjects: 16
Study 7658089 — intervention group
Group type: EXPERIMENTAL
Intervention: CVD 112 vaccine (10^6 cfu)
Number of subjects: 12
Study 7658089 — intervention group
Group type: EXPERIMENTAL
Intervention: CVD 112 vaccine (10^8 cfu)
Number of subjects: 12
Study 7658089 — intervention group
Group type: COMPARATOR
Intervention: Control (unvaccinated)
Number of subjects: 12
Study 7658089 — intervention group
Group type: EXPERIMENTAL
Intervention: CVD 112 vaccine
Number of subjects: 12
Study 7658089 — intervention group
Group type: COMPARATOR
Intervention: Primary wild type clinical infection
Number of subjects: 12
Study 2527546 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril
Number of subjects: 0
Study 2527546 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 0
Study 2527546 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril and Hydrochlorothiazide (combination)
Number of subjects: 0
Study 1104411 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone 20 mg daily (Pred)
Number of subjects: 120
Study 1104411 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone in doses given on alternate days and titrated (Pred‐Titrad)
Number of subjects: 120
Study 1104411 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of prednisone 10 mg and azathioprine 50 mg daily (Comb)
Number of subjects: 120
Study 1104411 — intervention group
Group type: COMPARATOR
Intervention: Placebo or azathioprine 100 mg daily (Control)
Number of subjects: 120
Study 31319810 — intervention group
Group type: EXPERIMENTAL
Intervention: Information
Number of subjects: 380
Study 31319810 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivation
Number of subjects: 380
Study 31319810 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural skills
Number of subjects: 380
Study 28527657 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief guided parent-delivered cognitive behavioural therapy (CBT)
Number of subjects: 136
Study 28527657 — intervention group
Group type: COMPARATOR
Intervention: Solution-focused brief therapy
Number of subjects: 136
Study 27037096 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based Palliative HF Program (HPHP) implemented for up to 12 months
Number of subjects: 0
Study 27037096 — intervention group
Group type: COMPARATOR
Intervention: Usual care (customary hospital-based care)
Number of subjects: 0
Study 27037096 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based Palliative HF Program (HPHP)
Number of subjects: 0
Study 24764200 — intervention group
Group type: COMPARATOR
Intervention: Paroxetine (10 mg/d) coadministration
Number of subjects: 13
Study 24764200 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (10 mg/d) coadministration
Number of subjects: 13
Study 21981418 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 134
Study 21981418 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 134
Study 20048527 — intervention group
Group type: EXPERIMENTAL
Intervention: Hylan G-F 20
Number of subjects: 1674
Study 17465663 — intervention group
Group type: COMPARATOR
Intervention: Kurasper F Bond (Conventional acid-etching and bonding system)
Number of subjects: 42
Study 17465663 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil Protect Bond (Two-step fluoride-releasing antibacterial self-etching primer and adhesive)
Number of subjects: 42
Study 17465663 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil tri‐S Bond (One-step self-etching primer and adhesive)
Number of subjects: 42
Study 15045129 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin 1 mg/kg BW s.c. b.i.d.
Number of subjects: 90
Study 15045129 — intervention group
Group type: COMPARATOR
Intervention: i.v. heparin aPTT‐adjusted daily for 8 +/- 2 days
Number of subjects: 90
Study 11476774 — intervention group
Group type: EXPERIMENTAL
Intervention: ZIFT
Number of subjects: 548
Study 11476774 — intervention group
Group type: COMPARATOR
Intervention: IVF-ET
Number of subjects: 548
Study 9164891 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase
Number of subjects: 20201
Study 9164891 — intervention group
Group type: COMPARATOR
Intervention: No streptokinase allergy
Number of subjects: 20201
Study 7962286 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged dopamine infusion (5 micrograms/kg.min, iv)
Number of subjects: 11
Study 7962286 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief dopamine administration (15‐ to 21‐h)
Number of subjects: 11
Study 7962286 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine withdrawal
Number of subjects: 11
Study 7962286 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine infusion
Number of subjects: 11
Study 3604396 — intervention group
Group type: EXPERIMENTAL
Intervention: Live rubella vaccine
Number of subjects: 33
Study 29659963 — intervention group
Group type: EXPERIMENTAL
Intervention: BUTTER (12.4-12.6% of energy as SFAs, 32% as fat, 52% as carbohydrates)
Number of subjects: 46
Study 29659963 — intervention group
Group type: EXPERIMENTAL
Intervention: MUFA (5.8% of energy as SFAs replaced with monounsaturated fatty acids from refined olive oil)
Number of subjects: 46
Study 29659963 — intervention group
Group type: COMPARATOR
Intervention: CHEESE (12.4-12.6% of energy as SFAs, 32% as fat, 52% as carbohydrates)
Number of subjects: 46
Study 29659963 — intervention group
Group type: COMPARATOR
Intervention: CHO (5.8% of energy as SFAs, 25.0% as fat, 59% as carbohydrates)
Number of subjects: 46
Study 29659963 — intervention group
Group type: EXPERIMENTAL
Intervention: BUTTER compared to CHEESE
Number of subjects: 46
Study 29659963 — intervention group
Group type: EXPERIMENTAL
Intervention: MUFA compared to CHEESE
Number of subjects: 46
Study 28161136 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac (50mg) with Codeine (50mg)
Number of subjects: 46
Study 28161136 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac (50mg) alone
Number of subjects: 46
Study 26335312 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral counseling (CBC)
Number of subjects: 277
Study 26335312 — intervention group
Group type: COMPARATOR
Intervention: Best practice (BP)
Number of subjects: 277
Study 23312567 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloperidone (24 mg/d, mean dose = 21.6 mg)
Number of subjects: 173
Study 23312567 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloperidone (12 mg/d, given once daily at bedtime)
Number of subjects: 173
Study 23312567 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 173
Study 23312567 — intervention group
Group type: COMPARATOR
Intervention: Ziprasidone
Number of subjects: 173
Study 20829339 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill exercise
Number of subjects: 14
Study 20829339 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycle exercise
Number of subjects: 14
Study 20829339 — intervention group
Group type: COMPARATOR
Intervention: Resting breathing (control)
Number of subjects: 14
Study 18458356 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium Bicarbonate (NaHCO(3)) 0.3 g/kg
Number of subjects: 6
Study 18458356 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 6.2 +/- 0.3 mg/kg
Number of subjects: 6
Study 18458356 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Sodium Bicarbonate and Caffeine (B+C)
Number of subjects: 6
Study 18458356 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 6
Study 16918260 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab
Number of subjects: 0
Study 16918260 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 12665753 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine injection plus heat probe coagulation
Number of subjects: 185
Study 12665753 — intervention group
Group type: COMPARATOR
Intervention: Epinephrine injection plus argon plasma coagulation
Number of subjects: 185
Study 10741842 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoor environmental conditions related to asthma triggers
Number of subjects: 112
Study 9280055 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA RT‐PCR
Number of subjects: 90
Study 8497702 — intervention group
Group type: EXPERIMENTAL
Intervention: Surfactant
Number of subjects: 17
Study 8497702 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 3320381 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 ppm NO2 gas exposure
Number of subjects: 10
Study 3320381 — intervention group
Group type: COMPARATOR
Intervention: Air exposure
Number of subjects: 10
Study 31532055 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimedia education
Number of subjects: 110
Study 31532055 — intervention group
Group type: COMPARATOR
Intervention: Routine training (Control)
Number of subjects: 110
Study 28866384 — intervention group
Group type: EXPERIMENTAL
Intervention: Partially hydrolyzed protein formula supplemented with nondigestible oligosaccharides
Number of subjects: 138
Study 28866384 — intervention group
Group type: COMPARATOR
Intervention: Standard cow's milk formula
Number of subjects: 138
Study 28116438 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive extraction
Number of subjects: 160
Study 28116438 — intervention group
Group type: COMPARATOR
Intervention: Traditional methods including use of orthodox chisel
Number of subjects: 160
Study 24297090 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin + Prednisolone
Number of subjects: 52
Study 24297090 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone
Number of subjects: 52
Study 24297090 — intervention group
Group type: COMPARATOR
Intervention: Sitagliptin
Number of subjects: 52
Study 24297090 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 23451480 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma radiofrequency ablation to the anterior extremity of the inferior turbinate
Number of subjects: 153
Study 23451480 — intervention group
Group type: COMPARATOR
Intervention: Total inferior turbinate ablation (Control)
Number of subjects: 153
Study 20224364 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal sterile barrier precautions (MSBPs)
Number of subjects: 424
Study 20224364 — intervention group
Group type: COMPARATOR
Intervention: Standard sterile barrier precaution (SSBP)
Number of subjects: 424
Study 19263664 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of fluor gel
Number of subjects: 14
Study 19263664 — intervention group
Group type: COMPARATOR
Intervention: Oral washing gel
Number of subjects: 14
Study 15992564 — intervention group
Group type: EXPERIMENTAL
Intervention: naltrexone
Number of subjects: 160
Study 15992564 — intervention group
Group type: EXPERIMENTAL
Intervention: acamprosate
Number of subjects: 160
Study 15992564 — intervention group
Group type: EXPERIMENTAL
Intervention: naltrexone plus acamprosate
Number of subjects: 160
Study 15992564 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 160
Study 11207224 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive red blood cell transfusion guidelines without erythropoietin administration
Number of subjects: 0
Study 11207224 — intervention group
Group type: COMPARATOR
Intervention: Erythropoietin administration
Number of subjects: 0
Study 9681219 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy (extended field, generally mantle, 3500 cGy)
Number of subjects: 307
Study 9681219 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (ABVD: adriamycin, bleomicin, vinblastine and dacarbazine, 6 monthly cycles)
Number of subjects: 307
Study 9681219 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (three cycles of ABVD followed by irradiation therapy and three more cycles of chemotherapy)
Number of subjects: 307
Study 8008405 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg of morphine
Number of subjects: 52
Study 8008405 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 2809191 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin (20 or 40 mg twice a day for 12 weeks)
Number of subjects: 188
Study 2809191 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin
Number of subjects: 188
Study 1222406 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparinized group
Number of subjects: 95
Study 1222406 — intervention group
Group type: COMPARATOR
Intervention: Nonheparinized group
Number of subjects: 95
Study 6996815 — intervention group
Group type: COMPARATOR
Intervention: Zopiclone 3.5 mg
Number of subjects: 0
Study 6996815 — intervention group
Group type: COMPARATOR
Intervention: Zopiclone 5 mg
Number of subjects: 0
Study 6996815 — intervention group
Group type: COMPARATOR
Intervention: Zopiclone 6 mg
Number of subjects: 0
Study 6996815 — intervention group
Group type: COMPARATOR
Intervention: Zopiclone 9 mg
Number of subjects: 0
Study 6996815 — intervention group
Group type: COMPARATOR
Intervention: Zopiclone 13.5 mg
Number of subjects: 0
Study 6996815 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6996815 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopiclone (all doses)
Number of subjects: 0
Study 31476741 — intervention group
Group type: EXPERIMENTAL
Intervention: L-Amino Acid (L-AA)
Number of subjects: 40
Study 31476741 — intervention group
Group type: EXPERIMENTAL
Intervention: Casein Glycomacropeptide (CGMP-AA)
Number of subjects: 40
Study 31476741 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 31476741 — intervention group
Group type: EXPERIMENTAL
Intervention: L-AA and CGMP-AA (immediate post-consumption)
Number of subjects: 40
Study 28330721 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (20,000 IU weekly)
Number of subjects: 94
Study 28330721 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 28330721 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Number of subjects: 94
Study 25536204 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast reduction group (BRG)
Number of subjects: 60
Study 25536204 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 60
Study 25082115 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative cognitive behavioural therapy for prolonged grief (PG‐CBT), 20‐25 sessions
Number of subjects: 51
Study 25082115 — intervention group
Group type: COMPARATOR
Intervention: Wait list control group (WG)
Number of subjects: 51
Study 22580858 — intervention group
Group type: EXPERIMENTAL
Intervention: infliximab + methotrexate
Number of subjects: 66
Study 22580858 — intervention group
Group type: EXPERIMENTAL
Intervention: etanercept or adalimumab
Number of subjects: 66
Study 22580858 — intervention group
Group type: COMPARATOR
Intervention: methotrexate
Number of subjects: 66
Study 19013259 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (200 mg twice daily for a minimum of 48 weeks)
Number of subjects: 56
Study 19013259 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 18210989 — intervention group
Group type: EXPERIMENTAL
Intervention: Interspinous process distractors
Number of subjects: 0
Study 15354103 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 90
Study 15354103 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative platelet dysfunction (measured by adenosine diphosphate aggregometry)
Number of subjects: 90
Study 15354103 — intervention group
Group type: COMPARATOR
Intervention: Algorithm-driven treatment of bleeding
Number of subjects: 90
Study 11581600 — intervention group
Group type: EXPERIMENTAL
Intervention: 21‐mm and 23‐mm St Jude Medical Hemodynamic Plus valves
Number of subjects: 125
Study 11581600 — intervention group
Group type: COMPARATOR
Intervention: 21‐mm and 23‐mm standard cuff valves
Number of subjects: 125
Study 11581600 — intervention group
Group type: EXPERIMENTAL
Intervention: 21‐mm Hemodynamic Plus valves
Number of subjects: 125
Study 11581600 — intervention group
Group type: EXPERIMENTAL
Intervention: 21‐mm and 23‐mm Hemodynamic Plus valves
Number of subjects: 125
Study 9893590 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified macular grid laser photocoagulation
Number of subjects: 20
Study 7736484 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg once daily for the first 4 weeks, increasing to 10 mg once daily for the second 4 weeks
Number of subjects: 315
Study 7736484 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 315
Study 7736484 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 315
Study 2927990 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose nebulized albuterol (0.15 mg/kg per dose)
Number of subjects: 32
Study 2927990 — intervention group
Group type: COMPARATOR
Intervention: Low-dose nebulized albuterol (0.05 mg/kg per dose)
Number of subjects: 32
Study 31825704 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week intensified augmented Berlin-Frankfurt-Münster (BFM) consolidation (IC)
Number of subjects: 5377
Study 31825704 — intervention group
Group type: COMPARATOR
Intervention: 4-week standard consolidation (SC)
Number of subjects: 5377
Study 31825704 — intervention group
Group type: EXPERIMENTAL
Intervention: Full COG-augmented BFM regimen for SR-high disease
Number of subjects: 5377
Study 31331773 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigational liquid Pentavalent (DTwP-Hb-Hib) combination vaccine
Number of subjects: 405
Study 31331773 — intervention group
Group type: COMPARATOR
Intervention: Pentavac SD® vaccine
Number of subjects: 405
Study 31331773 — intervention group
Group type: EXPERIMENTAL
Intervention: Both vaccines
Number of subjects: 405
Study 28256281 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Decision Aids (PDAs)
Number of subjects: 17
Study 26668145 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-incision laparoscopic cholecystectomy (SILC)
Number of subjects: 552
Study 26668145 — intervention group
Group type: COMPARATOR
Intervention: Traditional laparoscopic cholecystectomy (TLC)
Number of subjects: 552
Study 23425751 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily administration of the Confusion‐Assessment Method for ICU (intervention service)
Number of subjects: 283
Study 22091790 — intervention group
Group type: EXPERIMENTAL
Intervention: FFC‐AL intervention implemented by a function focused‐care nurse and a site‐identified champion over 12 months
Number of subjects: 171
Study 22091790 — intervention group
Group type: COMPARATOR
Intervention: FFC education only (Control)
Number of subjects: 171
Study 19672170 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture of Hegu (LI 4)
Number of subjects: 50
Study 19672170 — intervention group
Group type: COMPARATOR
Intervention: Needling of cutaneous and muscular point (sham acupuncture)
Number of subjects: 50
Study 19672170 — intervention group
Group type: COMPARATOR
Intervention: Without manipulation
Number of subjects: 50
Study 17405298 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific immunotherapy (SIT)
Number of subjects: 20
Study 17405298 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 15333852 — intervention group
Group type: EXPERIMENTAL
Intervention: Etidronate
Number of subjects: 349
Study 15333852 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium
Number of subjects: 349
Study 15333852 — intervention group
Group type: EXPERIMENTAL
Intervention: Etidronate + Calcium
Number of subjects: 349
Study 15333852 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 349
Study 11483080 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (325 mg every other day)
Number of subjects: 21216
Study 11483080 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21216
Study 9727365 — intervention group
Group type: EXPERIMENTAL
Intervention: Borderline Hypertension (BHT) subjects
Number of subjects: 20
Study 9727365 — intervention group
Group type: COMPARATOR
Intervention: Cold pressor test
Number of subjects: 20
Study 9727365 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma norepinephrine levels
Number of subjects: 20
Study 7980254 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary closure
Number of subjects: 63
Study 7980254 — intervention group
Group type: COMPARATOR
Intervention: T-tube drainage
Number of subjects: 63
Study 7980254 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 63
Study 2644923 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of moxalactam (1 g intravenously)
Number of subjects: 1027
Study 2644923 — intervention group
Group type: COMPARATOR
Intervention: Extended course of moxalactam (1 g intravenously for eight doses)
Number of subjects: 1027
Study 2644923 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (single dose and extended course)
Number of subjects: 1027
Study 1090358 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral 5-FU (20 mg/kg/day for 5 days)
Number of subjects: 100
Study 1090358 — intervention group
Group type: COMPARATOR
Intervention: Intravenous 5-FU (13.5 mg/kg/day for 5 days)
Number of subjects: 100
Study 1090358 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral 5-FU (for malignant hepatomegaly)
Number of subjects: 100
Study 1090358 — intervention group
Group type: COMPARATOR
Intervention: Intravenous 5-FU (for malignant hepatomegaly)
Number of subjects: 100